Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Head Neck. 2019 May;41(5):1282-1289. doi: 10.1002/hed.25551. Epub 2018 Dec 10.
To investigate the toxicity, changes of quality of life (QOL), and survival for patients with nasopharyngeal cancer (NPC) treated by concurrent chemoradiotherapy (CCRT) with simultaneously integrated boost volumetric-modulated arc therapy (SIB-VMAT).
A total of 68 NPC patients treated by CCRT with SIB-VMAT technique were collected. QOL was longitudinally assessed by the EORTC QLQ-C30 and HN35 questionnaires at the 4 time points: baseline, 42.4 Gy (20 fractions), and 3, 12 months after CCRT.
The 4-year locoregional relapse free, distant metastasis free, failure free, and overall survival rates were 97.0%, 86.4%, 82.0%, and 88.1%, respectively. The 4-year cumulative incidence rate of late toxicities with grade 3 or more was 3.0%. One year after CCRT, most QOL scales, except some oral related symptoms, recovered to baseline level.
CCRT with SIB-VMAT produces excellent locoregional control, few severe late toxicity, and good general health status for NPC patients.
为了研究接受同期放化疗（CCRT）同步整合boost 容积调强弧形治疗（SIB-VMAT）的鼻咽癌（NPC）患者的毒性、生活质量（QOL）变化和生存率。
共收集了 68 例接受 SIB-VMAT 技术 CCRT 治疗的 NPC 患者。通过 EORTC QLQ-C30 和 HN35 问卷在 4 个时间点（基线、42.4Gy（20 个分次）和 CCRT 后 3、12 个月）进行纵向评估 QOL。
4 年局部区域无复发生存率、远处无转移生存率、无失败生存率和总生存率分别为 97.0%、86.4%、82.0%和 88.1%。4 年累积 3 级及以上晚期毒性发生率为 3.0%。CCRT 治疗 1 年后，大多数 QOL 量表（除了一些口腔相关症状外）恢复到基线水平。
SIB-VMAT 同步整合 boost 容积调强弧形治疗为 NPC 患者提供了优异的局部区域控制效果、较少的严重晚期毒性和良好的总体健康状况。
